NCT03984006 is a clinical trial in Thyroid Diseases, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03984006?

NCT03984006 is sponsored by National Taiwan University Hospital.

What condition does NCT03984006 study?

NCT03984006 studies Thyroid Diseases, Heart Failure.

Is NCT03984006 still recruiting?

NCT03984006 is currently completed. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT03984006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Detection of Autoimmune Thyroid Heart Disease Via Urinary Exosomal Proteins

Completed Last updated 2 September 2021

What this trial tests

trial in Thyroid Diseases in 5 participants. Completed in 14 May 2021.

Timeline

28 June 2019

Primary endpoint
31 August 2020

14 May 2021

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5
Start date	28 June 2019
Primary completion	31 August 2020
Estimated completion	14 May 2021
Sites	1 location across Taiwan

Conditions studied

Thyroid Diseases — all drugs for Thyroid Diseases →
Heart Failure — all drugs for Heart Failure →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 80, any sex, with Thyroid Diseases or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autoimmune thyroid disease revealed close relationship with heart failure, including the entities of subclinical hyperthyroidism and hypothyroidism. Heart failure is a principal complication of all forms of heart disease. The American College of Cardiology defines HF as a complex clinical syndrome that impairs the ability of the ventricle to fill with or inject blood. In fact, it may be caused by a defect in myocardial contraction, by an impairment in ventricular filling with preserved systolic function ('diastolic HF') or by a combination of both. Earlier detection of probable trend of heart failure in subclinical thyroid diseases is very important in not only Taiwan, Pan-Asia, but all over the aging world. However, it is not currently available. The investigators will enroll 20 patients with subclinical hyperthyroidism, subclinical hypothyroidism, and collect their urine specimens in outpatient clinic per year. Prognostic biological markers via this prospective study. The study was designed as prospective pattern, and the investigators will enroll clinical and subclinical thyroid disease with quarterly follow-up, then detect urine exosomal proteins NT-proBNP. The investigators try to find the correlation of outcome with unknown/fresh biomarkers in this study with time-dependent manner. The investigators hope to find earlier predicting biomarkers for heart dysfunction in autoimmune thyroid disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Clinical applications for exosomes: Are we there yet?
Perocheau D, Touramanidou L, Gurung S, Gissen P, et al · · 2021 · cited 101× · PMID 33751579 · DOI 10.1111/bph.15432
The Role of Extracellular Vesicles in the Pathogenesis and Treatment of Autoimmune Disorders.
Lu M, DiBernardo E, Parks E, Fox H, et al · · 2021 · cited 52× · PMID 33732229 · DOI 10.3389/fimmu.2021.566299
Global requirements for manufacturing and validation of clinical grade extracellular vesicles.
Thakur A, Rai D. · · 2024 · cited 24× · PMID 40027307 · DOI 10.1016/j.jlb.2024.100278
Exosomes: Biological Pharmaceutical Nanovectors for Theranostics.
Thomas SC, Kim JW, Pauletti GM, Hassett DJ, et al · · 2021 · cited 18× · PMID 35096795 · DOI 10.3389/fbioe.2021.808614
Exosomal Biomarkers: A Comprehensive Overview of Diagnostic and Prognostic Applications in Malignant and Non-Malignant Disorders.
Delshad M, Sanaei MJ, Mohammadi MH, Sadeghi A, et al · · 2025 · cited 13× · PMID 40305328 · DOI 10.3390/biom15040587
Role of stem cell derivatives in inflammatory diseases.
Yang Y, Peng Y, Li Y, Shi T, et al · · 2023 · cited 13× · PMID 37006266 · DOI 10.3389/fimmu.2023.1153901
Unfathomed Nanomessages to the Heart: Translational Implications of Stem Cell-Derived, Progenitor Cell Exosomes in Cardiac Repair and Regeneration.
Thej C, Kishore R. · · 2021 · cited 8× · PMID 34359980 · DOI 10.3390/cells10071811

Verify or expand the search:

Other recruiting trials for Thyroid Diseases

Currently open trials in the same condition.

NCT07462195 — Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery · Phase 4 · recruiting
NCT07382973 — Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control · NA · recruiting
NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
NCT06730321 — Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03984006 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03984006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing